Cybin (NASDAQ:HELP) Stock Falls 5.6% - Should You Sell?

Key Points

• Cybin shares fell 5.6% to about $10.41 on Tuesday, with trading volume down 92% from the average session volume.
• Analyst sentiment remains broadly positive: six analysts rate the stock a Buy, with a consensus price target of $46.33, although one source recently downgraded it to Strong Sell.
• Cybin reported a quarterly loss of $0.91 per share, missing estimates of $0.80, while insiders bought approximately $8.4 million of stock over the past 90 days.

Cybin Inc. (NASDAQ:HELP - Get Free Report) traded down 5.6% on Tuesday. The company traded as low as $10.53 and last traded at $10.4130. 96,798 shares traded hands during trading, a decline of 92% from the average session volume of 1,253,279 shares. The stock had previously closed at $11.03.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on HELP shares. Wells Fargo & Company started coverage on Cybin in a research note on Monday, July 27th. They issued an "overweight" rating and a $16.00 target price on the stock. Wall Street Zen lowered Cybin from a "sell" rating to a "strong sell" rating in a report on Saturday, October 3rd. Barclays assumed coverage on Cybin in a research report on Friday, September 18th. They set an "overweight" rating and a $35.00 price target for the company. Finally, TD Cowen boosted their price target on Cybin from $8.00 to $62.00 and gave the company a "buy" rating in a report on Thursday, August 20th. Six research analysts have rated the stock with a Buy rating. Based on data from MarketBeat, the company has an average rating of "Buy" and a consensus price target of $46.33.

Cybin Stock Performance

The firm has a market capitalization of $830.36 million, a PE ratio of -3.45 and a beta of 0.53. The firm's 50 day moving average price is $12.13 and its 200-day moving average price is $7.85.

Cybin (NASDAQ:HELP - Get Free Report) last announced its quarterly earnings results on Friday, August 14th. The company reported ($0.91) earnings per share for the quarter, missing the consensus estimate of ($0.80) by ($0.11). On average, equities research analysts expect that Cybin Inc. will post -2.95 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Cybin news, insider Paul Glavine acquired 100,000 shares of the business's stock in a transaction dated Tuesday, September 8th. The stock was acquired at an average cost of $12.47 per share, for a total transaction of $1,247,000.00. Following the completion of the transaction, the insider directly owned 4,271,252 shares of the company's stock, valued at $53,262,512.44. This represents a 2.40% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Greg Cavers bought 3,000 shares of Cybin stock in a transaction dated Tuesday, September 29th. The shares were acquired at an average cost of $12.91 per share, with a total value of $38,730.00. Following the completion of the purchase, the chief financial officer owned 3,000 shares in the company, valued at approximately $38,730. This trade represents a ∞ increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders have acquired 688,000 shares of company stock valued at $8,422,830 over the last ninety days. 15.00% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Cybin

A number of large investors have recently added to or reduced their stakes in the stock. AXQ Capital LP purchased a new stake in shares of Cybin during the second quarter worth about $75,000. Farther Finance Advisors LLC raised its position in shares of Cybin by 927.4% during the 3rd quarter. Farther Finance Advisors LLC now owns 22,818 shares of the company's stock worth $280,000 after purchasing an additional 20,597 shares during the last quarter. Finally, Pale Fire Capital SE acquired a new position in shares of Cybin during the 2nd quarter worth about $1,015,000. 17.94% of the stock is currently owned by institutional investors and hedge funds.

About Cybin

Cybin Inc is a clinical-stage biotechnology company focused on developing psychedelic-based therapeutics for mental health conditions. The company combines psychedelic compounds with drug-delivery technologies and treatment protocols designed to improve the safety, consistency and duration of psychedelic-assisted therapies.

Cybin's development programs have included CYB003, an investigational deuterated psilocybin therapy being studied for major depressive disorder, and CYB004, an investigational formulation of N,N-dimethyltryptamine (DMT) being evaluated for generalized anxiety disorder.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.